Status:
UNKNOWN
Efficacy of Oral Administration of Trehalose in Patients With Parkinson Disease
Lead Sponsor:
Neuromed IRCCS
Conditions:
Parkinson Disease
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
Parkinson's disease (PD) is a neurodegenerative disease characterized by the neurodegeneration of substance nigra pars compacta (SNpc) and the formation of alpha-synuclein protein aggregates in neuron...
Eligibility Criteria
Inclusion
- Ability to provide written informed consent;
- PD diagnosis according to UK Parkinson's Disease Society Brain Bank Clinical Diagnostic Criteria (UKPDS);
- Age between 18 and 80 years (inclusive);
- Hoehn \& Yahr staging \> 1;
Exclusion
- Inability to provide written informed consent;
- Diagnosis of other concomitant neurodegenerative disease;
- Concomitant treatment with drugs similar to trehalose;
- Hypersensitivity or intolerance to the active substance administered;
- Severe swallowing problems;
- Participation in other interventional studies within 30 days from the screening;
- Other medical conditions that can interfere with results or endanger the participant.
Key Trial Info
Start Date :
May 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2023
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT05355064
Start Date
May 1 2022
End Date
May 1 2023
Last Update
May 2 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.